Syra Health Corp Reports Annual Meeting Voting Results

What Happened

• Syra Health Corp filed an 8-K on July 23, 2026 reporting results from its Annual Meeting of Stockholders. A quorum was represented with 13,664,105 shares in person or by proxy (including 350,000 Class B shares, each with 16.5 votes).
• All five nominees — Priya Prasad; Dr. Vijayapal R. Reddy; Dr. Ketan Paranjape; Dr. Avutu S. Reddy; and Radhika Mereddy — were elected to serve until the 2027 annual meeting. The company also ratified M&K CPAs, PLLC as its independent registered public accounting firm for fiscal year ending December 31, 2026, and approved an amendment to its 2022 Omnibus Equity Incentive Plan increasing Class A shares available to 4,100,000.

Key Details

• Total shares represented: 13,664,105 (includes 350,000 Class B shares with 16.5 votes each).
• Director vote examples: Priya Prasad — For 9,583,429; Abstain 1,656,430; Broker non-vote 2,424,246. Radhika Mereddy — For 9,416,873; Abstain 1,822,986; Broker non-vote 2,424,246.
• Auditor ratification: M&K CPAs, PLLC — For 12,133,305; Against 48,079; Abstain 1,482,721.
• Equity plan amendment: Increase to 4,100,000 Class A shares approved — For 8,548,265; Against 2,691,142; Abstain 452; Broker non-vote 2,424,246.

Why It Matters

• Board continuity: Electing the five nominees maintains the company’s current board slate through the 2027 meeting, which matters for corporate strategy and oversight.
• Audit continuity: Ratifying M&K CPAs, PLLC keeps audit arrangements in place for the 2026 fiscal year, reducing near-term uncertainty around financial reporting.
• Shareholder impact: Increasing the equity plan pool provides the company flexibility for stock-based compensation and hiring but also potentially increases future dilution; the substantial opposing votes on the plan (2.69M against) and broker non-votes indicate meaningful shareholder interest and some disagreement on the change.